Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance

Charles River Laboratories Intl. IncTrade
Hilton Hotels Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Hilton Hotels Corporation Common Stock trades at $314 (market cap $70.82B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 5.3× Charles River Laboratories Intl. Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLHLT
Market Cap
$13.46B$70.82B
Sector
HealthConsumer Cyclical
52-Week High
$282.00$350.22
52-Week Low
$145.57$256.75
Enterprise Value
$16.30B$83.83B
Dividend Yield
0.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Hilton Hotels Corporation Common Stock

Hilton Worldwide Holdings (HLT) trades at $323.16, up 3.91% over 24 hours, with a bullish analyst consensus of 57% buy ratings and a $352 price target. Recent earnings have consistently beaten estimates, with Q2 2026 EPS at $2.29 matching expectations. The stock shows bearish technical signals but strong fundamentals, including revenue growth to $12.04B in 2025 and a net income margin of 12.69%. However, rising debt levels and a high P/E ratio of 46.21 pose valuation concerns.

The outlook for HLT is positive due to robust travel demand and a growing hotel pipeline, though premium valuation and increasing debt require caution. Investment opportunity lies in sustained earnings growth and capital returns, while risks include economic sensitivity and labor disputes, as highlighted by ongoing strikes and soft Q3 guidance affecting investor sentiment.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Hilton Hotels Corporation Common Stock

Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.

Read more on HLT